IEX Rule 26
Print page |
Email page
Display all Answers
Below you will find information required for compliance with Rule 26 of the IEX Rules for Companies - ‘Company Information Disclosure’
Description of the business
Merrion Pharmaceuticals plc ('Merrion') is a speciality pharmaceutical company with operations in Ireland and the United States and is focused on the development of improved oral dosage forms of drugs with poor bioavailability. Merrion, founded in 2003, was formed to acquire a range of assets from Elan Corporation following the announcement that it was re-organising to focus on key therapeutic areas and was electing to dispose of its drug delivery businesses. Merrion is currently developing improved formulations of known drugs, which will allow: (i) the drug to be administered orally when previously it was in injectable form; and/or (ii) improve the bioavailability of an existing oral formulation. The company is developing these enhanced drug profiles using its patented drug delivery platforms GIPET and GIRES. It is also looking to develop the platforms as drug delivery options for companies bringing new drugs to the market.
Country of incorporation and main country of operations
Ireland
Directors and Responsibilities
Click here
Board Committees
Click here
Share Information
Click here
Company Announcements
Merrion Pharmaceuticals new facility is granted license to manufacture by Irish Medicines Board Result of AGM Merrion Pharmaceuticals Notification of Major Interests 21st May 2010 Merrion Block Listing Return 13th May 2010 Notification of Interests 13th May 2010 Merrion announces publication of annual return 13th May 2010 Merrion Pharmaceuticals Appoints Dr. Hing Kin Chan as Chief Business Officer Merrion Pharmaceuticals is issued a key US patent for their lead product Orazol™
Novo Nordisk starts Phase I trial with oral GLP1 analogue using Merrion Pharmaceutical's GIPET® technology
Merrion Pharmaceuticals Plc Announces Preliminary Results for the year ended 31 Dec 2009 Merrion Pharmaceuticals plc announces issuance of key United States Patent, 2nd March 2010 Novo Nordisk starts phase 1 trial with oral insulin analogue - Merrion Pharmaceuticals earns USD 2 million milestone payment 7th December 2009 Merrion Pharmaceuticals Plc Announce the Official Opening of their New State of the Art Facility in Citywest 29th Oct 2009 Merrion Pharmaceuticals Plc to Present at AACR-NCI-EORTC International Molecular Targets & Cancer Therapeutics Conference in Boston, MA Merrion Pharmaceuticals Plc Completion of Placing 15th Oct 2009 Merrion Pharmaceuticals selected to present at prestigious UBS Global Life Sciences conference, Monday 21st Sept 2009 Merrion Pharmaceuticals plc announces commencement of Second feasibility collaboration programme with the Swiss based Ferring Pharmaceuticals SA ,Dublin, Ireland – 14th September 2009 Merrion Pharmaceuticals plc Interim Results for the six months ended 30 June 2009, Dublin, Ireland 4th September 2009 Merrion Pharmaceuticals Announces Expansion of Capabilities -22nd July 2009 Merrion Pharmaceuticals Results of 2009 AGM -17th June 2009 Merrion Pharmaceuticals Plc Announces positive Final results on key Phase II Orazol™ study - 29th May 2009 Merrion Pharmaceuticals Plc
2008 Annual Report & Accounts - 19th May 2009 Merrion Pharmaceuticals Plc Announces Preliminary results on Phase II Orazol™ study – 15th May 2009 Merrion Pharmaceuticals Plc - Notification of Major Interests
Merrion Pharmaceuticals 2008 Annual Report.
Merrion Pharmaceuticals IEX Block Listing Return - 20 April 2009.
Merrion Pharmaceuticals Block Listing Application 20 April 2009.
Merrion Pharma Notification of interests of Directors and connected persons Merrion Pharmaceuticals Plc Announces Preliminary Results for the year ended 31 December 2008.
Merrion Pharmaceuticals Grant of Options 9th March 2009.
Merrion Pharmaceuticals Announces Board Changes 12th February 2009.
Merrion Completes Patient Enrolment in Phase IIb Study – 10th February 2009.
Merrion Announces License Agreement with Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) – Novo Nordisk makes equity investment in Merrion. Dublin, Ireland 16th January 2009.
Merrion Pharmaceuticals Grant of Options
Merrion Pharmaceuticals Appoints Harry Stratford to Board of Directors
Merrion Announces License Agreement with Novo Nordisk to Develop Oral Formulation of Insulin Analogues
Dublin, Ireland 24th November 2008
Merrion Pharmaceuticals receives 2008 Frost & Sullivan Osteoporosis Technology Innovation of the Year Award - Dublin, Ireland, Wednesday 5th November 2008
Merrion Pharmaceuticals Grant of Options 24 October 2008
Merrion Pharmaceuticals Share Listing Announcement 23 October 2008
Merrion Pharmaceuticals IEX Block Listing Return - 3rd Oct 2008
Merrion Pharmaceuticals Share Listing Announcement – 3rd Oct 2008
Merrion Pharmaceuticals announces chance to Board of Directors – 11th Sept 2008
Merrion Pharmaceuticals plc announces commencement of feasibility collaboration programme with the Swiss based Ferring Pharmaceuticals SA – 22nd September 2008
Merrion Pharmaceuticals Plc announce Interim Results for the six months ended 30 June 2008 - 12th Sept 2008
Merrion Pharmaceuticals plc announces commencement of next stage of oral drug research collaboration programme with Novo Nordisk
Grant of Options – July 10th 2008
Merrion Pharmaceuticals Appoints Dr John Fox as Chief Development Officer
Merrion Pharmaceuticals Plc Announces Result of AGM – July 7th 2008
Merrion Pharmaceuticals plc Appoints Paddy O'Sullivan to Board of Directors
Merrion Pharmaceuticals plc announces 2007 year end financial results
Merrion Pharmaceuticals plc announce change to Board of Directors
Block Listing Announcement
Merrion Pharmaceuticals plc announce change to Board of Directors
Merrion Pharmaceuticals plc Admission to IEX
Merrion Pharma Schedule One Announcement
IEX Schedule One
Merrion Pharma Schedule One Announcement
Merrion Pharma Conditional trading announcement
Number of IEX securities
16,583,768 Ordinary shares of €0.01
Restriction of shares
The Directors and certain Shareholders together representing 95.9% of the Enlarged Issued Share Capital have undertaken for a period of 180 days from the date of Admission, not to sell, assign, transfer, pledge, contract to sell or otherwise
dispose of any Ordinary Shares or any securities convertible into Ordinary Shares. Goodbody Corporate Finance may, in its sole discretion, release all or any portion of the Ordinary Shares subject to the lock-in arrangements.
Admission Document
Merrion Pharma Admission Document
Advisers
IEX Adviser :Broker :Solicitors to the Company :Auditors :Registrars :
Constitutional Documents
Memorandum
Articles of Association
Financial Information
Merrion Pharmaceuticals Notice of AGM
Merrion Pharmaceuticals 2009 Annual Report
Merrion_Pharmaceuticals_Notice of AGM
Merrion Pharmaceuticals 2008 Annual Report Merrion Pharmaceuticals Interim Report June 2008
Merrion_Pharmaceuticals_Notice of AGM
Merrion_Pharmaceuticals_2007_Annual_Report
Financial Information on Merrion Pharmaceutical Holdings Limited Financial Information on Merrion Pharmaceutical plc
Other Information
Bloomberg Symbol: MERR
JavaScript is not enabled. With JavaScript enabled, this page will display content dynamically.
show all
hide all